Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
Publishing timestamp: 2024-04-17 12:20:45
Summary
Eli Lilly's weight loss drug Zepbound showed potential to treat obstructive sleep apnea in patients with obesity in two late-stage clinical trials. The drug was more effective than placebo at reducing the severity of the condition. The results have led to a 2% increase in Eli Lilly's shares and could potentially lead to Medicare coverage for the drug.
Sentiment: POSITIVE
Keywords: breaking news, health care industry, science, eli lilly and co, biotechnology, business news, business, united states, pharmaceuticals, novo nordisk a/s, biotech and pharmaceuticals,